Panel Discuses Use of CD19 Bispecifics in Sequencing
Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
Read More
Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Read More
Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Read More
Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
Read More
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Read More
Medical experts highlight second-line options for treating patients with DLBCL.
Read More
Relapsed/Refractory Follicular Lymphoma: Future Directions in Care
Key opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.
Read More
Patient Scenario 2: A 53-Year-Old Man With Relapsed/Refractory FL
Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.
Read More
Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies
A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.
Read More
Relapsed/Refractory Follicular Lymphoma Treatment Armamentarium
Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.
Read More
Follicular Lymphoma: Patient Monitoring and Maintenance Therapy
Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.
Read More
Role of BTK Inhibitors in Relapsed/Refractory Follicular Lymphoma
A brief review of BTK inhibitor therapy and its potential role within the relapsed/refractory follicular lymphoma treatment landscape.
Read More
Patient Scenario 1: An 83 -Year-Old With Relapsed/Refractory FL
Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.
Read More
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Read More
Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023
Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
Read More
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Read More
Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.
Read More
Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
What is the Role of Bispecifics in Relapsed/Refractory DLBCL?
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
Read More
Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
Read More
Evolving Treatment Landscape of Relapsed/Refractory Follicular Lymphoma
A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.
Read More
Recent Treatment Guideline Updates in Follicular Lymphoma
Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.
Read More
Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Read More
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel
A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel
Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
Read More
Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL
Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Read More
Factors in Selecting Treatment for Relapsed/Refractory DLBCL
Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Overview of Relapsed/Refractory DLBCL and Management Strategies
Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Read More
Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma
Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
Read More